Slingshot members are tracking this event:

RINTEGA Product Profile Set to Expand - Celldex set to Initiate Additional Studies in Glioblastoma and Combination Treatments

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details As part of an ongoing initiative to expand RINTEGA's potential product profile, Celldex intends to initiate additional studies of RINTEGA in 2016.  One study is designed to evaluate RINTEGA when administered earlier in the treatment regimen in newly diagnosed glioblastoma, set to begin H2 2016.  The other looks at possible treatment of RINTEGA with the drug imiquimod, to be initiated March 2016.
Additional Relevant Details Discontinued in newly diagnosed glioblastoma.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 07, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Rintega, Glioblastoma, Imiquimod, Rindopepimut